The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A drug–drug interaction study of everolimus (an mTOR inhibitor) and JI-101, an orally active inhibitor of VEGF 2, PDGF, and EphB4 receptors, in patients with advanced urologic tumors.
N. Agarwal
No relevant relationships to disclose
M. Sahu
Consultant or Advisory Role - Vanthys
D. J. Abhyankar
Consultant or Advisory Role - Vanthys
T. L. Werner
No relevant relationships to disclose
B. Benjamin
Consultant or Advisory Role - Vanthys
N. R. Srinivas
Consultant or Advisory Role - Vanthys
S. Sharma
No relevant relationships to disclose